Registered title, quoted from ClinicalTrials.gov
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen Memorial Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07806292, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
At least one measurable lesion as defined by the following criteria: the longest diameter ≥ 10 mm for non-nodal lesions, or the short-axis diameter ≥ 15 mm for nodal lesions; confirmed unresectable HCC; Child-Pugh liver function score ≤ 7.
Inclusion criterion 3
Receipt of other investigational drugs or medical devices within 4 weeks prior to the first dose; or prior use of anti-tumor indicated drugs where less than 2 weeks or 5 drug half-lives (whichever is longer) have elapsed between the completion of previous treatment and the administration of the study drug, and adverse events caused by prior treatment have not recovered to ≤ CTCAE Grade 1.
Exclusion criterion 15
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
Inclusion criterion 7
Patients with a second primary cancer or multiple malignancies, except for HCC, carcinoma in situ of the cervix, and non-melanoma skin cancer, or a history of other malignancies previously diagnosed and explicitly cured for at least 5 years with no evidence of subsequent recurrence.
Exclusion criterion 4
Active hepatitis C (i.e., anti-HCV positive or HCV-RNA positive with abnormal liver function); known history of HIV infection.
Exclusion criterion 14
Pregnant or lactating women; sexually active men or women of childbearing potential who are unwilling or unable to use effective contraception.
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; blood tests: counts, liver and kidney function; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07806292, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age between 18 and 75 years, regardless of gender.
- Confirmed diagnosis of unresectable hepatocellular carcinoma (HCC) according to both the China Liver Cancer (CNLC) staging criteria and the American Association for the Study of Liver Diseases (AASLD) clinical diagnostic criteria.
- At least one measurable lesion as defined by the following criteria: the longest diameter ≥ 10 mm for non-nodal lesions, or the short-axis diameter ≥ 15 mm for nodal lesions; confirmed unresectable HCC; Child-Pugh liver function score ≤ 7.
- Naive to any local (ablation, hepatic arterial embolization/infusion therapy, liver transplantation) or systemic therapy (chemotherapy and/or molecular targeted therapy, immunotherapy; antiviral therapy excluded) for HCC at initial diagnosis, or patients with intrahepatic recurrence after previous radical resection.
- Expected survival time ≥ 12 weeks.
- No anti-HCC drugs (including modern traditional Chinese medicine preparations indicated for HCC: Lentinan Injection, Kanglaite Injection or Soft Capsules, Aidi or Kangsaidi Injection, Propaneed Oil, Huai'er Granules, and Ganfule Tablets) administered within 2 weeks prior to the first dose.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
- HBV DNA < 10\^4 copies/ml (2000 IU/ml). If HBV DNA ≥ 10\^4 copies/ml, antiviral therapy must be initiated first and continued until HBV DNA drops below 10\^4 copies/ml before entering the study, along with ongoing antiviral medication and monitoring of liver function and HBV viral load.
- Normal function of major organs, meeting the following criteria:
a) Hematology (no blood transfusion or G-CSF administered within 14 days prior to screening): i. Hemoglobin (Hb) ≥ 90 g/L; ii. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L; iii. Platelet count (PLT) ≥ 75 × 10\^9/L; b) Biochemistry (no albumin (ALB) administration within 14 days prior to testing): i. Albumin (ALB) ≥ 28 g/L; ii. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5.0 × upper limit of normal (ULN); iii. Total bilirubin (TBIL) ≤ 4.0 × ULN (patients with obstructive jaundice may be enrolled after percutaneous transhepatic cholangial drainage (PTCD)); iv. Creatinine ≤ 1.5 × ULN; v. Electrolytes essentially normal or normalized after treatment. c) Urinalysis: i. Urine protein ≤ 1+.
- The patient voluntarily consents to enrollment, signs the written informed consent form (ICF), and is able to comply with the required treatment and follow-up visits according to the protocol.
Exclusion Criteria:
- Histologically confirmed fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular-cholangiocarcinoma (HCC-ICC).
- Symptomatic moderate to massive pleural effusion/ascites.
- Obstructive jaundice, liver failure, or hepatic encephalopathy.
- Patients with a second primary cancer or multiple malignancies, except for HCC, carcinoma in situ of the cervix, and non-melanoma skin cancer, or a history of other malignancies previously diagnosed and explicitly cured for at least 5 years with no evidence of subsequent recurrence.
- Active bleeding or coagulation abnormalities (Prothrombin Time, PT > 16 s; Activated Partial Thromboplastin Time, APTT > 43 s; International Normalized Ratio, INR ≥ 2), bleeding tendency, or currently receiving thrombolytic, anticoagulant, or antiplatelet therapy.
- Concomitant use of medications that may prolong the QTc interval and/or induce Torsades de Pointes (TdP), or affect the metabolism of chemotherapeutic agents.
- Pregnant or lactating women; sexually active men or women of childbearing potential who are unwilling or unable to use effective contraception.
- Any significant clinical or laboratory abnormalities that, in the opinion of the investigator, would affect the safety evaluation, such as: uncontrolled active infection (> NCI-CTCAE v5.0 Grade 2), uncontrolled diabetes (> NCI-CTCAE v5.0 Grade 2), hypertension not controlled to below the specified range (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg) despite treatment with two or more antihypertensive drugs, peripheral neuropathy ≥ Grade 2 (NCI-CTCAE v5.0), congestive heart failure ≥ Grade 2 (NCI-CTCAE v5.0), myocardial infarction within 6 months, or thyroid dysfunction (> NCI-CTCAE v5.0 Grade 2), etc.
- History of brain metastases, subdural metastasis, or severe mental illness; patients suspected of central nervous system (CNS) metastases must be excluded by cranial MRI.
- History of gastrointestinal bleeding or definite predisposition to gastrointestinal bleeding within the past 3 months, such as known active ulcer lesions, or fecal occult blood ≥ ++ (not eligible for enrollment); if persistent fecal occult blood is positive, a gastroscopy examination is required.
- Severe gastric fundus/esophageal wall varices requiring interventional treatment.
- Occurrence of abdominal or gastrointestinal perforation or intra-abdominal abscess within 4 weeks prior to the first dose.
- Significant abnormality in glomerular filtration rate (estimated creatinine clearance < 60 ml/min or serum creatinine > 1.5 × ULN).
- Active hepatitis C (i.e., anti-HCV positive or HCV-RNA positive with abnormal liver function); known history of HIV infection.
- Receipt of other investigational drugs or medical devices within 4 weeks prior to the first dose; or prior use of anti-tumor indicated drugs where less than 2 weeks or 5 drug half-lives (whichever is longer) have elapsed between the completion of previous treatment and the administration of the study drug, and adverse events caused by prior treatment have not recovered to ≤ CTCAE Grade 1.
Quoted from ClinicalTrials.gov, NCT07806292, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07806292, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.